PAGENAX SOLUTION FOR INJECTION 120MG/ML
Brolucizumab, Solution for injection 120mg/ml
What it does
Brolucizumab is a medication used to treat eye conditions that cause vision problems.
Commonly used for: age-related macular degeneration, diabetic macular edema
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:23 · updated 2026-09-21 02:30:20
About brolucizumab
Brolucizumab is a medication used to treat eye conditions that cause vision problems.
What it treats
- age-related macular degeneration
- diabetic macular edema
How it works
It works by reducing swelling in the eye and preventing further vision loss.
Who it's for
This treatment is for adults with specific eye diseases that affect vision.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About for
For is a medication used to treat various conditions.
What it treats
- specific medical condition
How it works
For works by addressing the underlying issues related to the condition it treats.
Who it's for
For is suitable for individuals diagnosed with the specific medical condition.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Brolucizumab
BNF-referencedBrolucizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). It is primarily used in the treatment of certain retinal disorders, such as age-related macular degeneration (AMD) and diabetic macular edema. By blocking VEGF-A, brolucizumab suppresses endothelial cell proliferation, inhibits the growth of new blood vessels, and reduces retinal vascular permeability, thus helping to improve visual acuity in affected patients.
Indications
- Age-related macular degeneration (AMD)
- Diabetic macular edema (specialist use only)
Dosage
Children: Refer to the BNF for Children for appropriate dosages.
Adults: Initially, 6 mg once a month for the first 3 doses, then 6 mg every 6 weeks for the first 5 doses, to be administered into the affected eye.
Mechanism of action
Brolucizumab acts by binding to VEGF-A, preventing it from interacting with its receptors on endothelial cells. This inhibition leads to reduced angiogenesis (formation of new blood vessels) and decreased vascular permeability, which are key processes in the pathophysiology of diseases like AMD and diabetic macular edema.
Pharmacodynamics
The pharmacodynamic effects of brolucizumab include a significant reduction in retinal vascular leakage and the stabilization or improvement of visual acuity in patients with retinal diseases. The reduction in VEGF-A activity helps limit the progression of diseases characterized by abnormal blood vessel growth and leakage.
Pharmacokinetics
Brolucizumab is administered via intravitreal injection, allowing for localized action in the eye. The systemic absorption of the drug is limited, and it has a long half-life, which supports less frequent dosing. The pharmacokinetics can vary based on individual patient factors, including age, body weight, and the presence of any antibodies against the drug. Monitoring of intra-ocular pressure is recommended after administration.
Contra-indications
- History of intra-ocular inflammation
- History of retinal vascular occlusion
- Hypersensitivity to brolucizumab or any excipients
Adverse effects
- Intra-ocular inflammation
- Retinal vasculitis
- Retinal occlusion
- Endophthalmitis
- Eye discomfort
- Cataract
- Hemorrhage
- Myocardial infarction
- Stroke
- Arterial thromboembolism
Precautions
- Monitor intra-ocular pressure and visual acuity
- Monitor for signs of ocular infection following injection
- Patients should be advised to report any signs of infection immediately
- Female patients of childbearing potential should use effective contraception during treatment and for 1 month after
Pregnancy
Manufacturer advises to avoid unless potential benefit outweighs risk; limited information available.
Breast-feeding
Manufacturer advises to avoid during and for 1 month after treatment; no information available.
Storage
Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.
Formulations
- Solution for injection
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- ADRENALINE INJ 1MG/ML 1ML · Nairobi Pharmaceuticals
- ADVOCATE (FOR CATS) SOLUTION · Bayer
- ATRAPURE 2.5ML INJECTION · Nairobi Enterprises
- ATROMED INJECTION · Dawa
- ATROPINE · Reddys Pharma
- ATROPINE SULPHATE INJ. 0.6MG/ML 1ML · Nairobi Pharmaceuticals
- ALPHAGAN P · Allergan
- B-PROST 1 · Indoco Remedies
- BIOSULIN 30:70 · M.j Biopharm Pvt Ltd
- BIOSULIN N · M. J. Biopharm Pvt. Ltd
- BIOSULIN R · Mj Biopharm
- BUDONEB 0,25 MG/ML · Teva